Cambridge, UK, and Saluggia, Italy, 02 March 2020: TTP plc (TTP), a leading independent technology and product development company, and DiaSorin, a global leader in the in vitro diagnostic (IVD) field, have signed an exclusive licence and technology transfer agreement. DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.
TTP’s proprietary Puckdx platform offers a flexible, fast time-to-result and low-cost solution for translating diagnostic…
Cambridge, UK, 02 March 2020: PolyProx Therapeutics, a biotechnology company focused on the discovery and development of novel biopharmaceuticals for the treatment of cancer, today announces that it has raised an additional £1 million seed capital from new investor, LifeArc.
The additional funding will be used to deliver in vivo proof of concept data for polyproxin® molecule leads against two oncology drug targets. This data will form the basis for Series A financing in 2021. LifeArc joins existing investors, Cambridge Innovation Capital, RT Capital and Cambridge Enterprise.
PolyProx…
CAMBRIDGE, UK, 02 March 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced the successful close of its Series B funding. The Company has raised $30 million USD (£23 million GBP) in this round, which was led by new investor Foresite Capital. Existing investors, Draper Esprit, DCVC (Data Collective), the Morningside group, Providence Investment Company, Cambridge Consultants Ltd, Rising Tide Fund, and Civilization Ventures, also all participated in the round.
The new funding will be…
Christopher Good, Director of Cell and Gene Therapy Logistics at Biocair, will explore ongoing material sourcing challenges for organisations moving from development to clinical and commercial manufacturing in an upcoming webinar taking place on 12 March 2020.
Critical considerations in ensuring patient access to cell and gene therapies, and continued industry growth, include proper understanding of how to manage source material quality and supply chain continuity. The following areas will be covered:
• The importance of defining source material requirements for translation of allogeneic…
Cambridge, UK, 25th February 2020 / Sciad Newswire / One Nucleus is pleased to announce the launch of a new careers conference in Cambridge for students, employers and employees in the life sciences industry: “Building Life Science Adventures: A Conference on Creating the Best Careers and Teams.” The one-day event will be a chance to fill knowledge gaps and share best practice amongst academia and industry.
The conference will take place on Thursday 19th March 2020 from 09:00 - 16:00 at Anglia Ruskin University, Cambridge. With an expert…
Cambridge UK: 26 February 2020: Cerba Research has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs both of the Partner and the interests of One Nucleus members.Sofie Vandevyver, Head of Business Operations & Marketing, Cerba Research declared ‘we are proud of having formed this exciting new alliance with One Nucleus. We are confident this collaboration will allow us to bring people together and drive our leadership position within the field of precision medicine.’
Tony Jones, CEO of One Nucleus expands further ‘…
The EZ PREP efficiently isolate highly purified peripheral blood mononuclear cells from AMSBIO is designed to efficiently isolate highly purified peripheral blood mononuclear cells (PBMCs) from fresh whole blood products by density gradient centrifugation.The unique EZ PREP tube design provides greater visibility of your target cell population, allowing you to maximise your recovery of mononuclear cells. As a result, PBMCs are immediately available for downstream applications such as flow cytometry, culture, and/or DNA/RNA isolation.By making targeting and…
Cambridge and Leeds, UK, 25th February 2020 / Sciad Newswire / Domainex Ltd., a fully integrated provider of drug discovery services from its Medicines Research Centre near Cambridge, UK, has entered into a research partnership with LUNAC Therapeutics Limited to discover novel anticoagulant therapies that have a reduced risk of bleeding compared to current therapies.
The aim of the partnership is to discover a drug that inhibits the protease target, activated Factor XII. This coagulation factor is implicated in the formation of pathological clots, but not the stemming of bleeding, so…
Arecor Achieves Second License Milestone Payment from Global Pharmaceutical Partner
Arecor formulated biosimilar product progressing through clinical studies
Cambridge, UK., 25 February 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has achieved an important second, contractual milestone with one of its pharmaceutical partners. The first milestone was triggered in October 2017 following the signature of a license agreement between the parties.
In accordance with the license agreement…